
STAT+: Overton won’t get a vote before midterms
Health department nominees await Senate votes, and we map out what the elections mean for healthy policy.
148 stories found

Health department nominees await Senate votes, and we map out what the elections mean for healthy policy.

In this edition of STAT Health Tech: Oura delays IPO plans, Anthropic joins an clinical AI effort by ARPA-H, and MAHA's health data goals.

AstraZeneca is teaming up with Summit Therapeutics to test its PD-1/VEGF bispecific ivonescimab alongside AstraZeneca’s antibody-drug conjugates.

Novo has agreed to pay up to $2.6 billion to license an experimental, weekly weight loss pill from China’s Hengrui Pharma

A new study in mice led by Washington University in St. Louis researchers suggests that stopping certain immune cells from entering the brain could limit neurodegeneration.

"We should not make families poorer and then punish them for their poverty," write Sandy Santana and Kristen Weber of the National Center for Youth Law.

“National security begins in childhood,” write Tina L. Cheng, Stanley McChrystal, and James M. Perrin.

Big shifts in health care policy could emerge depending on who wins the midterms, affecting hospitals and pharma companies.

New medical devices deemed "breakthrough" by the FDA are no longer automatically eligible for extra Medicare payments.

Jennifer Reich has spent two decades speaking to families about their immunization decisions. In an interview, she unpacks what she's learned.

At a MAHA Institute event, Kennedy and others argued that health data should be more accessible to researchers can study vaccines, chronic diseases, and autism

Post-wildfire air quality needs to be monitored long term, suggests a study finding Maui residents had high levels of toxic metals months later.

Merck discontinued Recarbio, an important antibiotic in the U.S., despite concerns over resistance to superbugs.

The Trump administration asked the Supreme Court on Monday to let it enforce, for now, restrictions on gender-affirming care in federal prison.

Health insurance premiums are skyrocketing, private equity hospital chain goes nonprofit, and more from STAT's Health Care Inc.

The FDA has approved AbbVie’s once-daily Parkinson’s pill for sales, based on a late-stage study that showed the drug helped improve symptoms.

Blockbuster GLP-1 drugs have transformed the lives of millions of people. Lately, they’re undergoing a makeover of their own.

President Trump is canceling nearly $1 billion in spending approved by Congress, and most of the cuts are focused on HHS programs that serve refugees and unaccompanied minors.

Our finding was remarkable because it had remained hidden within one of the best-studied organs in medical history.

“Defenses against AI-created bioweapons will take years to build. We don’t have years to spare,” writes Ashish Jha.